Lebwohl, M., B. Strober, M. Linaberry, K. Hoyt, S. Banerjee, R. M. Kisa, and N. N. Mehta. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Lipid Parameters in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s115, doi:10.25251/skin.7.supp.115.